Impact of Anthracyclines on Diabetes Mellitus Development in B-Cell Lymphoma Patients: A Nationwide Population-based Study

Original Research Article
  • 10 Downloads

Abstract

Background and Objectives

Although anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma, adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application. We assessed whether anthracycline treatment also increases the risk for diabetes mellitus in patients with B-cell lymphoma.

Methods

Using data obtained from the Taiwanese National Health Insurance Research Database from 2004 to 2011, we compared overall survival and clinical features for B-cell lymphoma patients administered anthracyclines (n = 3147) and those not administered anthracyclines (n = 837). The impact of anthracycline treatment on diabetes risk was further investigated using a Gray’s test and multivariate competing-risk regression models in a dose-dependent manner.

Results

Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11–2.75; p = 0.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities. Cumulative anthracycline doses of 253–400 mg (HR: 2.35; 95% CI 1.41–3.91; p = 0.0010), 401–504 mg (HR: 2.26; 95% CI 1.26–4.05; p = 0.0063), and > 504 mg (HR: 2.29; 95% CI 1.25–4.18; p = 0.0072) increased the incidence density of diabetes in a dose-dependent manner (p = 0.0006). The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p = 0.4924).

Conclusion

Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients. Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment.

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Funding

This work was supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10701010021), Taiwan Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

Ethical approval

The institutional review board of the China Medical University Hospital approved this study (CMUH104-REC2-115). For this type of study, formal informed consent is not required by the institutional review board.

References

  1. 1.
    Coiffier B, Thieblemont C, Den Van, Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial G. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell’olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:1506–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016;122:3145–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Xu L, Wu X, Hu C, Zhang Z, Zhang L, Liang S, Xu Y, Zhang F. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials. Onco Targets Ther. 2016;9:4061–74.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Khan AA, Ashraf A, Singh R, Rahim A, Rostom W, Hussain M, Renner I, Collins NJ. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity. Intern Med J. 2016.  https://doi.org/10.1111/imj.13305.Google Scholar
  7. 7.
    Laribi K, Denizon N, Bolle D, Truong C, Besancon A, Sandrini J, Anghel A, Farhi J, Ghnaya H, Baugier de Materre A. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol. 2016;95:1705–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Chang KH, Hwang WL, Muo CH, Hsu CY, Teng CJ. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study. Support Care Cancer. 2016;24:4993–5000.CrossRefPubMedGoogle Scholar
  9. 9.
    van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Raemaekers JM, Kremer LC, Stovall M, Aleman BM, van Leeuwen FE. Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma. J Clin Oncol. 2014;32:3257–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Arunachalam S, Tirupathi Pichiah PB, Achiraman S. Doxorubicin treatment inhibits PPARgamma and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models. FEBS Lett. 2013;587:105–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Biondo LA, Lima Junior EA, Souza CO, Cruz MM, Cunha RD, Alonso-Vale MI, Oyama LM, Nascimento CM, Pimentel GD, Dos Santos RV, Lira FS, Rosa Neto JC. Impact of doxorubicin treatment on the physiological functions of white adipose tissue. PLoS One. 2016;11:e0151548.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    de Lima Junior EA, Yamashita AS, Pimentel GD, De Sousa LG, Santos RV, Goncalves CL, Streck EL, de Lira FS, Rosa Neto JC. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J Cachexia Sarcopenia Muscle. 2016;7:615–25.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Heart EA, Karandrea S, Liang X, Balke ME, Beringer PA, Bobczynski EM, Zayas-Bazan Burgos D, Richardson T, Gray JP. Mechanisms of doxorubicin toxicity in pancreatic beta-cells. Toxicol Sci. 2016;152:395–405.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lin CH, Sheu WH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273:102–10.CrossRefPubMedGoogle Scholar
  15. 15.
    Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993;19:197–228.CrossRefPubMedGoogle Scholar
  16. 16.
    Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast. 2012;21:142–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Geetha A, Sankar R, Devi CS. Effect of alpha-tocopherol on peroxidative membrane damage caused by doxorubicin: an in vitro study in human erythrocytes. Indian J Exp Biol. 1989;27:274–8.PubMedGoogle Scholar
  18. 18.
    Chen SY, Chiu CH. Worldwide molecular epidemiology of norovirus infection. Paediatr Int Child Health. 2012;32:128–31.CrossRefPubMedGoogle Scholar
  19. 19.
    Thibault V, Belanger M, LeBlanc E, Babin L, Halpine S, Greene B, Mancuso M. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. Diabetol Metab Syndr. 2016;8:71.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lee SY, Kurita N, Yokoyama Y, Seki M, Hasegawa Y, Okoshi Y, Chiba S. Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Support Care Cancer. 2014;22:1385–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7:214–20.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I, Havsteen H, Hansen M. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8:1806–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18:721–6.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Chieh-Lin Jerry Teng
    • 1
    • 2
    • 3
  • Kuang-Hsi Chang
    • 4
  • I-Ju Tsai
    • 5
  • Wen-Li Hwang
    • 1
  • Chung Y. Hsu
    • 6
  • Wayne H-H Sheu
    • 7
  1. 1.Division of Hematology/Medical Oncology, Department of MedicineTaichung Veterans General HospitalTaichungTaiwan
  2. 2.Department of Life ScienceTunghai UniversityTaichungTaiwan
  3. 3.School of MedicineChung Shan Medical UniversityTaichungTaiwan
  4. 4.Graduate Institute of Biomedical SciencesChina Medical UniversityTaichungTaiwan
  5. 5.Management Office for Health DataChina Medical University HospitalTaichungTaiwan
  6. 6.Graduate Institute of Clinical Medical ScienceChina Medical UniversityTaichungTaiwan
  7. 7.Division of Endocrinology and Metabolism, Department of MedicineTaichung Veterans General HospitalTaichungTaiwan

Personalised recommendations